IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Recent Developments in Tumor Targeting Drug Delivery Systems: A Comprehensive Review

Dhruba kishore paul[1], Udipta paul[2] , Mouly mitra[3], : These authors contributed equally to this review.

Author and Affiliations

1. Masters of pharmacy in pharmacology (senior associate on Wipro LTD.)
2. Masters of pharmacy in pharmaceutics (CALCUTTA INSTITUTE OF PHARMACEUTICAL TECHNOLOGY & ALLIED HEALTH SCIENCES)
3. Bachelor of pharmacy (STUDENT AT GLOBAL COLLEGE OF PHARMACEUTICAL TECHNOLOGY)

Abstract:-

Tumor targeting drug delivery systems have gained significant attention as a promising approach to improve the efficacy and safety of cancer therapies. This comprehensive review highlights recent developments in this field, encompassing various strategies and advancements. Passive targeting strategies exploit the enhanced permeability and retention effect and size-based targeting for preferential accumulation of drug-loaded carriers in tumors. Active targeting strategies utilize ligand-mediated, antibody-mediated, aptamer-mediated, and nanobody-based approaches to enhance specificity by selectively binding to tumor-specific receptors. Stimuli-responsive targeting strategies, including pH-responsive, enzyme-responsive, and temperature-responsive systems, enable triggered drug release within the tumor microenvironment. Nanoparticle-based drug delivery systems have seen remarkable progress, particularly lipid-based, polymer-based, and metal-based nanoparticles, offering improved drug encapsulation, controlled release, and enhanced targeting capabilities. Notably, nanocarriers designed for nucleic acid delivery, such as lipid nanoparticles for RNA delivery and polymeric nanoparticles for gene delivery, hold great promise for gene-based cancer therapies. .This comprehensive review provides an overview of the recent developments in this field, focusing on various strategies and technologies employed for efficient and specific drug delivery to tumor sites.

Keywords:- tumor targeting, drug delivery systems, passive targeting, active targeting, stimuli-responsive, nanoparticle-based, nucleic acid delivery, lipid nanoparticles, polymer-based nanoparticles, metal-based nanoparticles, exosomes, antibody-drug conjugates, peptide-based, characterization techniques, biocompatibility, safety assessment.

1. Introduction:-

The recent developments in tumor targeting drug delivery systems offer great promise for improving cancer treatment outcomes. By combining advances in nanotechnology, stimuli-responsive systems, antibody-drug conjugates, and gene delivery, researchers are striving to overcome the limitations of conventional cancer therapies. These targeted delivery systems have the potential to enhance drug efficacy, reduce side effects, and improve patient outcomes in the fight against cancer. As further research and clinical trials

progress, we anticipate the translation of these innovations into clinically viable treatments, ultimately benefiting cancer patients worldwide.[1]

1.1. Background on tumor targeting drug delivery systems:-

Cancer remains one of the leading causes of death worldwide, necessitating the development of more effective and targeted treatment strategies. Tumor targeting drug delivery systems have emerged as a promising approach to overcome these limitations by delivering therapeutic agents directly to cancer cells while sparing healthy tissues. One of the key objectives of tumor targeting drug delivery systems is to enhance the therapeutic index of anticancer drugs. This is achieved by improving drug delivery efficiency, increasing drug concentration at the tumor site, and minimizing systemic exposure and off-target effects.[1]

1.2. Importance of tumor targeting in cancer therapy:-

tumor targeting plays a vital role in cancer therapy by enhancing therapeutic efficacy, minimizing systemic toxicity, overcoming drug resistance, enabling personalized medicine approaches, facilitating combination therapies, aiding in early detection and diagnosis, and potentially reducing treatment costs. As research and development in tumor targeting continue to advance, these approaches hold great promise in improving cancer treatment outcomes and patient quality of life.[2]

2. Strategies for tumor targeting:-

There are several strategies employed in tumor targeting to ensure the delivery of therapeutic agents specifically to cancer cells while minimizing exposure to healthy tissues. These strategies leverage the unique characteristics of tumors or employ targeted delivery systems to achieve precise localization.[3]

2.1. Passive targeting strategies:-

Passive targeting strategies in tumor targeting focus on exploiting the unique physiological characteristics of tumors to achieve selective accumulation of therapeutic agents within cancerous tissues. These strategies do not involve the active targeting of specific tumor-associated antigens or receptors but rather take advantage of the natural properties of tumors. the effectiveness of passive targeting can vary depending on tumor type, stage, and individual patient characteristics.[3]

2.1.1. Enhanced permeability and retention effect:-

The Enhanced Permeability and Retention (EPR) effect is a crucial phenomenon in tumor biology that has been extensively studied and utilized in passive tumor targeting strategies. It describes the increased permeability of tumor blood vessels and impaired lymphatic drainage in solid tumors, resulting in the accumulation and retention of macromolecules and nanoparticles within the tumor microenvironment. it is important to note that the EPR effect is highly heterogeneous and can vary among different tumors and even within different regions of the same tumor. Factors such as interstitial fluid pressure, tumor perfusion, and tumor microenvironment can influence the extent of the EPR effect. Therefore, optimizing drug delivery systems and treatment protocols to exploit the EPR effect requires careful consideration of these tumor-specific characteristics.[3]

2.2.Active targeting strategies:-

Active targeting strategies in tumor targeting involve the specific recognition and binding of therapeutic agents to tumor-specific markers or receptors expressed on the surface of cancer cells. This approach aims to enhance the selectivity and efficiency of drug delivery to tumors while minimizing exposure to healthy tissues. Active targeting strategies typically involve the use of ligands, antibodies, peptides, or aptamers that can bind to tumor-specific antigens. Combining active targeting strategies with other

approaches, such as passive targeting or stimuli-responsive systems, can further enhance drug delivery efficiency and therapeutic outcomes in cancer treatment.[3]

2.2.1. Ligand-mediated targeting:-

ligand-mediated targeting strategies exploit the molecular recognition and binding properties of ligands to selectively deliver therapeutic agents to cancer cells expressing specific receptors. This approach enhances the specificity of drug delivery, reduces off-target effects on healthy tissues, and improves the therapeutic index of anticancer treatments. On going research continues to explore and develop novel ligands and targeting approaches to optimize ligand-mediated tumor targeting in cancer therapy.[3] Example is the use of peptides as targeting ligands. Peptide-based targeting strategies have shown promise in various applications, including cancer imaging, drug delivery, and receptor-mediated cancer cell internalization.

2.2.2. Antibody-mediated targeting:-

Antibody-mediated targeting is a specific type of ligand-mediated targeting that involves the use of monoclonal antibodies (mAbs) to selectively deliver therapeutic agents to cancer cells. Antibodies are large proteins produced by the immune system that can recognize and bind to specific antigens, including those present on the surface of cancer cells. Antibody-mediated targeting offers several advantages, including high specificity, affinity, and potential for personalized medicine. Several antibody-based therapies, including ADCs and immune checkpoint inhibitors, have been approved for the treatment of various cancers.[4]

2.2.3. Aptamer-mediated targeting:-

Aptamer-mediated targeting is an active targeting strategy that utilizes aptamers, which are short single-stranded DNA or RNA molecules, to specifically recognize and bind to target molecules, including those present on the surface of cancer cells. Aptamers are generated through a process called SELEX (Systematic Evolution of Ligands by EXponential enrichment), where a library of random sequences is subjected to iterative rounds of selection and amplification to identify aptamers with high affinity and specificity for the target molecule. Aptamers offer several advantages in targeted drug delivery, including high specificity, stability, and ease of synthesis. Aptamer-mediated targeting offers several advantages, including high specificity, low immunogenicity, and chemical stability.[5]

2.2.4. Nanobodies for targeting:-

Nanobodies, also known as single-domain antibodies or VHHs (variable domain of heavy-chain antibodies), are small antibody fragments derived from camelid species, such as llamas or camels. Nanobodies have gained significant interest in recent years as targeting agents in cancer therapy due to their unique properties, including small size, high stability, solubility, and high affinity for target molecules.[6]

2.3. Stimuli-responsive targeting strategies:-

Stimuli-responsive targeting strategies involve the design and utilization of drug delivery systems that respond to specific stimuli present in the tumor microenvironment. These systems are engineered to release therapeutic agents or exhibit targeted behavior in response to specific triggers, such as pH, temperature, enzymatic activity, redox potential, light, or magnetic fields. The goal of stimuli-responsive targeting is to enhance the specificity and efficacy of drug delivery by ensuring that the therapeutic agent is released or activated primarily at the tumor site.[7]

2.3.1. pH-responsive systems:-

pH-responsive drug delivery systems are designed to respond to the acidic pH found in the tumor microenvironment. The characteristic feature of many solid tumors is their acidic extracellular pH, which can range from pH 6.5 to 7.0, compared to the slightly alkaline pH (~7.4) of normal tissues. pH-responsive drug delivery systems take advantage of this pH differential to achieve targeted drug release at the tumor site. pH-responsive drug delivery systems provide several advantages, including selective drug release at the tumor site, reduced systemic toxicity, and improved therapeutic efficacy.[8]

2.3.2. Enzyme-responsive systems:-

Enzyme-responsive drug delivery systems are designed to respond to specific enzymes present in the tumor microenvironment. Tumor tissues often exhibit altered enzymatic activity, with certain enzymes being overexpressed or present in higher concentrations compared to healthy tissues. By utilizing enzyme-responsive systems, drug release can be triggered by enzymatic activity, allowing for targeted and controlled delivery of therapeutic agents.[9]

2.3.3. Temperature-responsive systems:-

Temperature-responsive drug delivery systems are designed to respond to changes in temperature, particularly the higher temperatures found in tumor tissues compared to healthy tissues. These systems utilize the temperature differential to trigger drug release or enhance drug uptake at the tumor site.[10]

3. Recent developments in tumor targeting drug delivery systems:-

Recent developments in tumor targeting drug delivery systems have shown significant advancements in improving the specificity, efficiency, and safety of cancer therapies. Here are some notable recent developments in this field.

3.1. Nanoparticles-based drug delivery systems:-

Nanoparticle-based drug delivery systems utilize nanoscale particles to deliver therapeutic agentsto specific targets in the body, including tumor tissues. These systems offer several advantages over conventional drug delivery methods, such as improved drug stability, enhanced bioavailability, prolonged circulation time, and targeted delivery.

3.1.1. Lipid-based nanoparticles:-

Lipid-based nanoparticles are a type of nanoparticle that are composed primarily of lipids, which are natural or synthetic molecules with hydrophilic (water-loving) and hydrophobic (water-repelling) regions. These nanoparticles are widely used in drug delivery systems due to their biocompatibility, versatility, and ability to encapsulate both hydrophilic and hydrophobic drugs.[11]

3.1.2. Polymer-based nanoparticles:-

Polymer-based nanoparticles are a class of nanoparticles composed of synthetic or natural polymers that have gained significant attention in the field of drug delivery. These nanoparticles offer several advantages, including tunable properties, biocompatibility, and versatility in encapsulating a wide range of therapeutic agents.[11,12]

Types of Polymers:-

a. Synthetic Polymers:- Synthetic polymers, such as poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), poly(caprolactone) (PCL), and polyethyleneimine (PEI), are commonly used for the formulation of polymer-based nanoparticles.

b. Natural Polymers: Natural polymers, such as chitosan, alginate, gelatin, and hyaluronic acid, are derived from biological sources and are biocompatible and biodegradable.

3.1.3. Metal-based nanoparticles:-

Metal-based nanoparticles have emerged as a promising class of materials for various applications, including drug delivery. These nanoparticles are typically composed of metals or metal compounds and offer unique properties and functionalities that can be harnessed for targeted drug delivery. Some key aspects of metal-based nanoparticles in drug delivery Gold Nanoparticles (AuNPs), Iron Oxide Nanoparticles (IONPs), Silver Nanoparticles (AgNPs), Quantum Dots (QDs),[11]

3.2. Nanocarriers for nucleic acid delivery:-

Nanocarriers play a crucial role in the delivery of nucleic acids, such as DNA, RNA, and siRNA, to target cells for various therapeutic applications. Nucleic acids are large and negatively charged molecules that face several barriers, such as degradation by nucleases and poor cellular uptake, hindering their efficient delivery. Nanocarriers can protect nucleic acids, facilitate their intracellular delivery, and enhance therapeutic outcomes. Each nanocarrier system has its advantages and considerations, including stability, biocompatibility, payload capacity, and immunogenicity.[13]

3.2.1. Lipid nanoparticles for RNA delivery:-

Lipid nanoparticles (LNPs) have emerged as a highly effective and widely used platform for the delivery of RNA-based therapeutics, including small interfering RNA (siRNA), messenger RNA (mRNA), and microRNA (miRNA). LNPs offer several advantages, such as high encapsulation efficiency, stability, biocompatibility, and the ability to facilitate cellular uptake and endosomal escape. [13]

3.2.2. Polymeric nanoparticles for gene delivery:-

Polymeric nanoparticles for gene delivery continue to be an active area of research, with efforts focused on improving delivery efficiency, minimizing cytotoxicity, enhancing target specificity, and overcoming biological barriers. Advancements in polymer design, surface engineering, and formulation techniques hold great potential for the development of safe and effective gene therapies.[14]

3.3. Targeted drug delivery using exosomes:-

Targeted drug delivery using exosomes has gained significant interest as a promising approach in the field of drug delivery. Exosomes are small extracellular vesicles that are naturally secreted by various cell types, including immune cells, stem cells, and cancer cells. They play a crucial role in intercellular communication by transferring bioactive molecules, such as proteins, lipids, and nucleic acids, between cells.[15]

3.4. Antibody-drug conjugates:-

Antibody-drug conjugates (ADCs) are a class of biotherapeutic agents designed to selectively deliver potent cytotoxic drugs to target cells. ADCs combine the specificity of monoclonal antibodies (mAbs) with the cytotoxic effects of small-molecule drugs, resulting in a targeted and potent treatment approach. ADCs consist of three main components: a monoclonal antibody (mAb), a linker, and a cytotoxic drug payload.

3.5. Peptide-based drug delivery systems:-

Peptide-based drug delivery systems are a class of delivery vehicles that utilize peptides for the targeted delivery of therapeutic agents to specific cells or tissues. Peptides are short chains of amino acids that can be engineered to exhibit various properties, such as targeting specificity, cell-penetrating ability, and drug encapsulation/release. Their ability to specifically interact with target cells, penetrate cell membranes, and encapsulate/transport a variety of therapeutic agents makes them attractive for the development of personalized and precision medicine strategies.[16]

4. Characterization techniques for tumor targeting drug delivery systems:-

Characterization techniques play a crucial role in evaluating and understanding the properties and performance of tumor targeting drug delivery systems. These techniques provide valuable insights into the physicochemical properties, drug encapsulation/release kinetics, targeting efficacy, stability, and safety of the delivery systems.

4.1. Imaging techniques for in vitro and in vivo evaluation:-

Imaging techniques play a crucial role in the evaluation of tumor targeting drug delivery systems both in vitro and in vivo. These techniques enable the visualization, characterization, and quantification of the distribution, behavior, and interaction of the delivery systems with cells, tissues, and organs. These imaging techniques offer valuable insights into the behaviour, biodistribution, and targeting efficacy of tumor targeting drug delivery systems in preclinical and clinical settings. Depending on the specific research objectives and properties of the delivery systems, a combination of these techniques can be employed to obtain a comprehensive understanding of their in vitro and in vivo performance. Commonly used imaging techniques for in vitro and in vivo evaluation of tumor targeting drug delivery systems, fluorescence Microscopy, Confocal Microscopy, Electron Microscopy, Flow Cytometry. Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), Optical Imaging, Computed Tomography (CT), etc. [17]

4.2. Analytical methods for assessing drug release kinetics:-

Analytical methods play a crucial role in assessing the drug release kinetics from drug delivery systems. These methods allow for the quantitative determination of the amount of drug released over time, providing valuable insights into the release profile, kinetics, and mechanisms of drug release. Some commonly used analytical methods for assessing drug release kinetics. UV-Visible Spectroscopy, igh-Performance Liquid Chromatography (HPLC), Liquid Chromatography-Mass Spectrometry (LC-MS), Fourier-Transform Infrared Spectroscopy (FTIR), Nuclear Magnetic Resonance (NMR) Spectroscopy, Electrochemical Methods. These analytical methods offer valuable insights into the release kinetics, mechanisms, and behavior of drugs from drug delivery systems. Depending on the specific characteristics of the system and the drug being released, a combination of these techniques may be employed to obtain a comprehensive understanding of the drug release profile.[18]

4.3. Biocompatibility and safety assessment:-

Biocompatibility and safety assessment are crucial aspects of evaluating tumor targeting drug delivery systems. These assessments aim to ensure that the delivery systems are well-tolerated by the body, do not cause significant toxicity, and have minimal adverse effects. Some commonly employed methods for assessing the biocompatibility and safety of tumor targeting drug delivery systems. Hemolysis Assay, Inflammatory Response Assessment , Immunogenicity Assessment, Genotoxicity Assessment, Organ Toxicity Evaluation, Pharmacokinetic Studies, It is important to note that the choice of assessment methods may vary depending on the specific characteristics of the drug delivery systems and the intended application. A combination of these methods, along with additional specialized assays, may be employed to comprehensively evaluate the biocompatibility and safety of tumor targeting drug delivery systems. [16]

5. Challenges and Future Perspectives:-

5.1.Overcoming biological barriers:-

Overcoming biological barriers is a critical aspect of tumor targeting drug delivery systems to ensure effective and efficient delivery of therapeutic agents to the tumor site. Several biological barriers exist in the body that can impede the successful delivery of drugs to tumors. Some strategies that have been developed to overcome these barriers, Extracellular Matrix (ECM) Barrier, Blood-Brain Barrier (BBB), Cellular Uptake and Intracellular Delivery, Immune System Clearance, Tumor Heterogeneity, Tumor Microenvironment,

By developing strategies to overcome these biological barriers, tumor targeting drug delivery systems can improve drug accumulation, enhance therapeutic efficacy, and minimize off-target effects, bringing us closer to more effective cancer treatments.[19]

5.2. Clinical translation and regulatory considerations:-

Clinical translation and regulatory considerations play a crucial role in the successful development and implementation of tumor targeting drug delivery systems. Some key aspects to consider, Preclinical Evaluation, Regulatory Approval, Clinical Trial Design, Safety Assessment, Regulatory Submissions. Successful translation of tumor targeting drug delivery systems from the laboratory to clinical practice requires addressing regulatory and manufacturing challenges, ensuring scalability, reproducibility, and cost-effectiveness.[19]

5.3. Integration of combination therapies:-

The integration of combination therapies has emerged as a promising approach in cancer treatment, and it holds great potential for enhancing the effectiveness of tumor targeting drug delivery systems. Combination therapies involve the simultaneous or sequential administration of multiple therapeutic agents or modalities to target different pathways or mechanisms of cancer progression. By combining different therapeutic agents or modalities, these approaches can enhance treatment efficacy, overcome drug resistance, minimize toxicity, and provide personalized treatment options. Continued research and development in this field will pave the way for more effective and individualized cancer therapies.[20]

5.4. Personalized medicine and targeted therapy:-

personalized medicine and targeted therapy represent a paradigm shift in healthcare, moving towards individualized treatment approaches. By leveraging molecular profiling and targeted interventions, personalized medicine and targeted therapy offer the potential for more effective, precise, and patient-centric cancer treatments.

Benefits of personalized medicine and targeted therapy. Improved Treatment Efficacy , Reduced Side Effects , Treatment Optimization, Tailored Treatment Plans, Early Detection and Prevention.

The relationship between personalized medicine and targeted therapy lies in their shared objective of tailoring treatment to the individual patient. In the context of cancer treatment, personalized medicine seeks to identify specific genetic alterations or biomarkers unique to a patient's tumor, while targeted therapy utilizes drugs or interventions that specifically address those alterations. By identifying the molecular drivers of a patient's cancer and matching them with appropriate targeted therapies, personalized medicine enables more effective and precise treatment.[20]

Conclusion:-

This review article provides a comprehensive overview of recent developments in tumor targeting drug delivery systems, highlighting various strategies, technologies, and challenges. The advancement of these systems holds great promise for

improving the efficacy and safety of anticancer therapies, ultimately leading to the field is rapidly evolving, and on-going research efforts are focused on addressing challenges, improving efficacy, and moving towards personalized and targeted treatments for improved patient outcomes.

1. Yasuhiro Matsumura HM. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Res. 1986;46:6387–92.[PubMed] [Google Scholar]
2. Wagner V, Dullaart A, Bock AK. et al. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24:1211–7. [PubMed] [Google Scholar]
3. Mohamed F Attia, Nicolas Anton, Justine Wallyn, Ziad Omran, Thierry F Vandamme. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. 2019 Aug;71(8):1185-1198. doi: 10.1111/jphp.13098. Epub 2019 May 3.
4. Fatma Betul Arslan, Kivilcim Ozturk Atar, Sema Calis. Antibody-mediated drug delivery . 2021 Mar 1;596:120268. doi: 10.1016/j.ijpharm.2021.120268. Epub 2021 Jan 21.
5. Silvia Catuogno,Carla L. Esposito,,Vittorio de Franciscis. Aptamer-Mediated Targeted Delivery of Therapeutics: An Update. 2016 Dec; 9(4): 69. Published online 2016 Nov 3. doi: 10.3390/ph9040069.
6. Karen De Vlaminck , Ema Romão , Janik Puttemans , Ana Rita Pombo Antunes , Daliya Kancheva , Isabelle Scheyltjens , Jo A Van Ginderachter , Serge Muyldermans , Nick Devoogdt , Kiavash Movahedi , Geert Raes . Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha. 2021 Nov 30;12:777524. doi: 10.3389/fimmu.2021.777524. eCollection 2021.
7. Sheng Wang, Peng Huang, and Xiaoyuan Chen. Stimuli-Responsive Programmed Specific Targeting in Nanomedicine. ACS Nano 2016, 10, 3, 2991–2994.Publication Date:February 16, 2016 https://doi.org/10.1021/acsnano.6b00870.
8. Chao Wang , Yiyang Zhang , Yu Shao , Xiancheng Tiana, Jiafang Piao , Yuanchen Dong , Dongsheng Liu a. pH-responsive Frame-Guided Assembly with hydrophobicity controllable peptide as leading hydrophobic groups. https://www.sciencedirect.com/science/article/pii/S2666542520300060.
9. Mahsa Shahriari , Mahsa Zahiri , Khalil Abnous , Seyed Mohammad Taghdisi , Mohammad Ramezani , Mona Alibolandi . Enzyme responsive drug delivery systems in cancer treatment . 2019 Aug 28;308:172-189. doi: 10.1016/j.jconrel.2019.07.004. Epub 2019 Jul 8.
10. Mahdi Karimi , Parham Sahandi Zangabad , Alireza Ghasemi , Mohammad Amiri , Mohsen Bahrami , Hedieh Malekzad , Hadi Ghahramanzadeh As , Zahra Mahdieh , Mahnaz Bozorgomid , Amir Ghasemi , Mohammad Reza Rahmani Taji Boyuk , and Michael R. Hamblin. Temperature-Responsive Smart Nanocarriers for Delivery Of Therapeutic Agents: Applications and Recent Advances. ACS Appl. Mater. Interfaces 2016, 8, 33, 21107–21133 . Publication Date:June 28, 2016.
11. Ahmad N., Sharma S., Alam M. K., Singh V. N., Shamsi S. F., Mehta B. R., et al. (2010). Rapid Synthesis of Silver Nanoparticles Using Dried Medicinal Plant of Basil. Colloids Surf. B. Biointerfaces 81, 81–86. 10.1016/j.colsurfb.2010.06.029 [PubMed] [CrossRef] [Google Scholar]
12. Alomrani A., Badran M., Harisa G. I., ALshehry M., Alshamsan A., Alkholief M., et al. (2019). The Use of Chitosan-Coated Flexible Liposomes as a Remarkable Carrier to Enhance the Antitumor Efficacy of 5-fluorouracil against Colorectal Cancer. Saudi Pharm. J. 27, 603–611. 10.1016/j.jsps.2019.02.008 [PMC free article] [PubMed] [CrossRef] [Google Scholar].
13. Anitha A., Maya S., Deepa N., Chennazhi K. P., Nair S. V., Jayakumar R. (2012b). Curcumin-loaded N,O-carboxymethyl Chitosan Nanoparticles for Cancer Drug Delivery. J. Biomater. Sci. Polym. Ed. 23, 1381–1400. 10.1163/092050611x581534 [PubMed] [CrossRef] [Google Scholar]
14. Raj Rai , Saniya Alwani , Ildiko Badea . Polymeric Nanoparticles in Gene Therapy: New Avenues of Design and Optimization for Delivery Applications . 2019 Apr 25;11(4):745. doi: 10.3390/polym11040745 .

15. Rumiana Tenchov, Janet M. Sasso, Xinmei Wang, Wen-Shing Liaw, Chun-An Chen, and Qiongqiong Angela Zhou . Exosomes—Nature's Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics. 2022 Nov 22; 16(11): 17802–17846. Published online 2022 Nov 10. doi: 10.1021/acsnano.2c08774.
16. Dmitriy Berillo , Adilkhan Yeskendir , Zharylkasyn Zharkinbekov , Kamila Raziyeva, Arman Saparov. Peptide-Based Drug Delivery Systems . 2021 Nov 5;57(11):1209. doi: 10.3390/medicina57111209.
17. Feng Chen, Hao Hong, Yin Zhang, Hector F. Valdovinos, Sixiang Shi,Glen S. Kwon, Charles P. Theuer, Todd E. Barnhart,and Weibo Cai. In Vivo Tumor Targeting and Image-Guided Drug Delivery with Antibody-Conjugated, Radiolabeled Mesoporous Silica Nanoparticles . :ACS Nano. 2013 Oct 22; 7(10): 10.1021/nn403617j. Published online 2013 Oct 1. doi: 10.1021/nn403617j .
18. Thomas Moore, Hongyu Chen, Rachel Morrison,Fenglin Wang, Jeffrey N. Anker, and Frank Alexis . Nanotechnologies for Noninvasive Measurement of Drug Release . Mol Pharm. 2014 Jan 6; 11(1): 24–39. Published online 2013 Nov 26. doi: 10.1021/mp400419k .
19. Daniel Rosenblum, Nitin Joshi, Wei Tao, Jeffrey M. Karp,corresponding author, and Dan Peercorresponding author. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018; 9: 1410. Published online 2018 Apr 12. doi: 10.1038/s41467-018-03705-y.
20. Olga M. Kutova, Evgenii L. Guryev, Evgeniya A. Sokolova, Razan Alzeibak, and Irina V. Balalaeva. Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency . Cancers (Basel). 2019 Jan; 11(1): 68. Published online 2019 Jan 10. doi: 10.3390/cancers11010068 .